Fortrea Q3: Margins Improve, But Revenue Conversion Still Lags

What happened

Fortrea's Q3 2026 results showed adjusted EBITDA up 14.4% year over year to $58 million, with adjusted EPS of $0.28, reflecting continued cost discipline. Revenue still declined, extending the streak of organic contraction, while book-to-bill of 1.12x indicates positive new orders but at a slightly lower rate than Q1's 1.15x. Management highlighted expanded early clinical trial capacity as a signal of revenue stabilization and growth potential, but backlog quality remains a watchpoint given past conversion issues. The improvement aligns with the cost-led margin repair phase of the turnaround, but does not yet confirm the demand-led revenue inflection required for the bull case. For a stock that has already rallied ~300% from its 2025 lows, these results are supportive but not sufficient to justify a buy at current valuation without clearer signs of organic revenue stabilization.

Implication

The Q3 data slightly improves the odds of the base case, but does not elevate the bull case probability materially because revenue decline persists and backlog burn is not reported. Holding or adding here requires belief that expanded capacity and positive book-to-bill will translate into organic growth within the next two quarters, which remains uncertain given FSP weakness. The sell discipline remains: trim above $20, as the master report suggests, because the valuation already discounts much of the recovery. Conversely, a pullback toward the attractive entry of $14 would offer a better risk-reward for those who want to position for a potential demand inflection. Key watchpoints for the next quarter: whether organic revenue moves to flat or positive, backlog burn improves above 8.5%, and free cash flow turns positive without increased use of the receivables facility.

Thesis delta

The new Q3 results reinforce the cost-led margin improvement but do not alter the core concern: revenue is still declining and backlog quality is unproven. The book-to-bill of 1.12x remains positive, and expanded capacity is encouraging, but these are forward indicators that have not yet converted into actual revenue stabilization. Consequently, the 'POTENTIAL SELL' stance remains appropriate; the bull case strengthens only mildly, and the base case still dominates, with the stock still below the $20 trim level.